IL118590A - Pharmaceutical composition for minimizing bone loss - Google Patents

Pharmaceutical composition for minimizing bone loss

Info

Publication number
IL118590A
IL118590A IL11859096A IL11859096A IL118590A IL 118590 A IL118590 A IL 118590A IL 11859096 A IL11859096 A IL 11859096A IL 11859096 A IL11859096 A IL 11859096A IL 118590 A IL118590 A IL 118590A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
bone loss
minimizing bone
minimizing
loss
Prior art date
Application number
IL11859096A
Other languages
English (en)
Other versions
IL118590A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL118590A0 publication Critical patent/IL118590A0/xx
Publication of IL118590A publication Critical patent/IL118590A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
IL11859096A 1995-06-06 1996-06-06 Pharmaceutical composition for minimizing bone loss IL118590A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss

Publications (2)

Publication Number Publication Date
IL118590A0 IL118590A0 (en) 1996-10-16
IL118590A true IL118590A (en) 1999-10-28

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11859096A IL118590A (en) 1995-06-06 1996-06-06 Pharmaceutical composition for minimizing bone loss

Country Status (22)

Country Link
US (1) US5599822A (fr)
EP (1) EP0747054B1 (fr)
JP (1) JPH11507051A (fr)
KR (1) KR19990022498A (fr)
CN (1) CN1192145A (fr)
AU (1) AU696209B2 (fr)
BR (1) BR9608389A (fr)
CA (1) CA2223055A1 (fr)
CO (1) CO4700446A1 (fr)
CZ (1) CZ382997A3 (fr)
DE (1) DE69623074T2 (fr)
EA (1) EA000763B1 (fr)
ES (1) ES2181849T3 (fr)
HU (1) HUP9900849A3 (fr)
IL (1) IL118590A (fr)
NO (1) NO975581L (fr)
PL (1) PL323935A1 (fr)
TR (1) TR199701507T1 (fr)
TW (1) TW372969B (fr)
WO (1) WO1996039138A1 (fr)
YU (1) YU34396A (fr)
ZA (1) ZA964778B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
WO2001035946A2 (fr) * 1999-11-15 2001-05-25 New Millennium Pharmaceutical Research, Inc. Administration intranasale de raloxifene et de tamoxifene
EP1113007A1 (fr) 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (fr) * 2000-08-15 2002-02-20 Octagene GmbH Hormones stéroidiennes comme agents de transfert
CA2490580C (fr) 2002-07-22 2012-12-11 Eli Lilly And Company Modulateurs selectifs des recepteurs oestrogeniques contenant un groupe naphtalene
CA2567056A1 (fr) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions et methodes ameliorees d'administration par les muqueuses de l'hormone parathyroide
ES2568259T3 (es) * 2004-05-13 2016-04-28 Alza Corporation Aparato y método para la administración transdérmica de agentes de hormona paratiroidea
WO2007044375A2 (fr) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Formulations pth et procédés d'utilisation
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
ZA964778B (en) 1997-12-08
CA2223055A1 (fr) 1996-12-12
YU34396A (sh) 1999-07-28
EP0747054B1 (fr) 2002-08-21
AU696209B2 (en) 1998-09-03
CN1192145A (zh) 1998-09-02
US5599822A (en) 1997-02-04
EP0747054A2 (fr) 1996-12-11
NO975581D0 (no) 1997-12-03
EA199800013A1 (ru) 1998-06-25
EP0747054A3 (fr) 1997-03-05
BR9608389A (pt) 1999-05-04
WO1996039138A1 (fr) 1996-12-12
HUP9900849A3 (en) 1999-11-29
TW372969B (en) 1999-11-01
AU6043096A (en) 1996-12-24
CO4700446A1 (es) 1998-12-29
IL118590A0 (en) 1996-10-16
EA000763B1 (ru) 2000-04-24
DE69623074D1 (de) 2002-09-26
DE69623074T2 (de) 2003-05-08
ES2181849T3 (es) 2003-03-01
JPH11507051A (ja) 1999-06-22
NO975581L (no) 1997-12-03
KR19990022498A (ko) 1999-03-25
PL323935A1 (en) 1998-04-27
CZ382997A3 (cs) 1998-09-16
HUP9900849A2 (hu) 1999-09-28
TR199701507T1 (xx) 1998-02-21

Similar Documents

Publication Publication Date Title
HUP9802086A3 (en) Pharmaceutical composition for piperidinoalkanol compounds
HU9601698D0 (en) Pharmaceutical composition
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
ZA967827B (en) Pharmaceutical compositions
IL118590A (en) Pharmaceutical composition for minimizing bone loss
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
ZA961051B (en) Pharmaceutical composition
GB9525194D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
IL118573A (en) Pharmaceutical compositions for minimizing bone loss
HU9602822D0 (en) Pharmaceutical composition
HK1087642A1 (en) Sterile pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
HUP9602732A2 (en) Pharmaceutical composition comprising lanperisone
HK1105807A1 (en) Sterile pharmaceutical composition
ZA961389B (en) Pharmaceutical composition for piperidinoalkanol compounds
SI0812195T1 (en) Pharmaceutical composition for piperidinoalkanol compounds
GB9517063D0 (en) Pharmaceutical composition
ZA9510132B (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees